David Schilansky
FounderCo-founder & Non-executive Chairman at Home Biosciences
Greater Paris Metropolitan Region
FoundedHome Biosciences
About
David Schilansky is Chief Executive Officer of Ariceum Therapeutics, a Radio Ligand Therapy company, and previously co-founded and led Home Biosciences, a biotech venture builder involved in launching One Biosciences, Sequantrix, and Apikal Therapeutics. From 2011 to 2019 he co-headed DBV Technologies, overseeing two IPOs on Euronext and Nasdaq that raised more than one billion US dollars in total, and earlier held finance leadership roles at Ipsen, including Group Chief Financial Officer, after beginning his career in M&A at Warburg Dillon Read and later leading Technicolor's investor relations team. He is a graduate of Dauphine University in Paris and holds a postgraduate qualification from Imperial College London.
Co-founder & Non-executive Chairman at Home Biosciences
Intro paths
In turn, David can intro founders to Home Biosciences's investors below.
Home Biosciences's investors · 2
Co-founders at Home Biosciences
Experience
- Ariceum TherapeuticsGroup CEOcurrent2025 — presentBerlin, Germany
- Ariceum TherapeuticsGroup CFO2025Basel, Switzerland
- Home BiosciencesCo-founder & chairmancurrent2020 — presentParis, Île-de-France, France
- One BiosciencesCo-Founder & President & Board Member representing Home Biosciencescurrent2020 — presentParis, Île-de-France, France
- Sequantrix GmbHChairman of the Boardcurrent2023 — presentAachen, North Rhine-Westphalia, Germany
- LYSOGENEIndependent Board member2016 — 2022Neuilly-sur-Seine, Île-de-France, France
- DBV TechnologiesDeputy CEO (directeur général délégué)2015 — 2019Greater Paris Metropolitan Region
- DBV TechnologiesCFO / COO2011 — 2015Greater Paris Metropolitan Region
- IpsenDeputy CFO / CFO2010 — 2011
- IpsenVice President, Finance2006 — 2011
- Thomson SAIRO2002 — 2006
- UBSM&A associate1999 — 2002
- Translink SA M&AM&A analyst1997 — 1998
Skills & more
+11 more
ValuationFinancial ModelingMergers & AcquisitionsFinancial AuditsBusiness DevelopmentFinancial AnalysisConsolidationDue Diligencecompany creationLeadershipManagementLanguages English · French
From David's professional profile.
Frequently asked questions
- Who is David Schilansky?
- David Schilansky is Chief Executive Officer of Ariceum Therapeutics, a Radio Ligand Therapy company, and previously co-founded and led Home Biosciences, a biotech venture builder involved in launching One Biosciences, Sequantrix, and Apikal Therapeutics. From 2011 to 2019 he co-headed DBV Technologies, overseeing two IPOs on Euronext and Nasdaq that raised more than one billion US dollars in total, and earlier held finance leadership roles at Ipsen, including Group Chief Financial Officer, after beginning his career in M&A at Warburg Dillon Read and later leading Technicolor's investor relations team. He is a graduate of Dauphine University in Paris and holds a postgraduate qualification from Imperial College London.
- Where does David Schilansky work?
- David Schilansky is Co-founder & Non-executive Chairman of Home Biosciences.
- What companies did David Schilansky found?
- David Schilansky founded Home Biosciences.
- Where did David Schilansky go to school?
- David Schilansky studied at Imperial College London (MSc, Finance); Université Paris Dauphine - PSL (Masters, Finance).
Founder mafias
Imperial College London mafia260
Also came through, then founded or led a company.
+ 253 more
UBS mafia52
Also came through, then founded or led a company.
+ 45 more
Université Paris Dauphine - PSL mafia29
Also came through, then founded or led a company.
+ 22 more
Dbv Technologies mafia2
Also came through, then founded or led a company.
Home Biosciences mafia2
Also came through, then founded or led a company.
Same school
Also attended Imperial College London562
+ 556 more
Also attended Université Paris Dauphine - PSL218
+ 212 more
